One mission,
one team
neuroClues' mission
In a world where neurological disorders will affect 1 person in 3 and where the number of Parkinson’s patients will double in the next decade, reaching 13 million patients, our mission is to empower clinicians with biomarkers allowing them to identify neurological disorders (Parkinson’s Disease, Alzheimer’s Disease, and Multiple Sclerosis) years before visible symptoms.
Our goal is to support 10M patients by 2030.
We are…
- a pragmatic healthcare company empowering people.
- ambitious. We are coming with an innovation that aims to disrupt the current clinical practice of neurologists
- trustworthy. We are researchers, doctors & engineers, inspired by science and passionate about the benefits of eye-tracking for the daily use of health practioners.
neuroClues' mission
In a world where neurological disorders will affect 1 person in 3 and where the number of Parkinson’s patients will double in the next decade, reaching 13 million patients, our mission is to empower clinicians with biomarkers allowing them to identify neurological disorders (Parkinson’s Disease, Alzheimer’s Disease, and Multiple Sclerosis) years before visible symptoms.
Our goal is to support 10M patients by 2030.
We are…
- a pragmatic healthcare company empowering people.
- ambitious. We are coming with an innovation that aims to disrupt the current clinical practice of neurologists
- trustworthy. We are researchers, doctors & engineers, inspired by science and passionate about the benefits of eye-tracking for the daily use of health practioners.
P3Lab was co-founded in 2020 by Pierre Daye, Pierre Pouget and Antoine Pouppez, former ICM and IBA employees. Pierre Daye earned his PhD in the applied mathematics department of UCLouvain in Belgium working on modeling and analysis of eye and head coordination. He did a series of post-docs and met PIerre Pouget, recognized CNRS researcher working with key opinion leaders in neuroscience at the Institute for Brain and Spinal Cord (ICM) in Paris. Together they pursued studies of eye movements through modeling and experimental research projects. During their combined +35 years of research, they faced the pains linked with the use of eye tracking and decided with the help of Antoine Pouppez to tackle these issues and develop a medical device (NeuroClues™) based on eye tracking to support early diagnose of neurological diseases and allows eye tracking to deliver its full potential to the clinical practice.
In November 2021, the team raised a € 4,7 million Seed round to bring this disruptive deep tech innovation to the European and US markets.
We are an empowering organisation with a strong culture of Trust, Respect, Quality, and Pragmatism.
The team consists of about 20 collaborators spread on 2 offices:
- the headquarter with the manufacturing facility in Louvain-la-Neuve, Belgium and
- an office located at La Pitié Salpétrière, iPEPS, the first incubator dedicated to brain diseases in France.